Author:
Tsoi E. I.,Vyshlov E. V.,Trusov V. B.
Abstract
The article shows the results of the study using drug Ropren in the patients with acute coronary syndrome. Ropren is a plant drug containing polyprenols — dolichol precursors which take part in dolichol phosphate pathway. The pathology in this pathway leads to disbalance and glycoprotein deficiency. This is the reason of large group of diseases. This study is randomized double blind placebo controlled (No. NCT03122340 at ClinicalTrials.gov). Patients (n=68) with ACS taking standard therapy including atorvastatin 40 mg/day were randomized into to 2 groups: group 1 (n=34) took Ropren 8 drops 3 times per day for 3 week, then 5 drops 3 times per day for 5 weeks; group 2 (n=34) took placebo in the same dose regimen. After two — month therapy there was a positive dynamic (decreasing) in the level of interleukin-6 in the study group whereas in the control group there was no statistically significant change: 4.36 (2.61, 8.95) and 5.5 (3.3; 8.4) pg/ml, respectively (p<0.05). In the group of patients taking Ropren the reduction or cessation of statin was required significantly less than in the placebo group: 3 (8.8%) vs 9 (26.5%), respectively. One patient from the first group had a side effect in the form of gravity in the right hypochondrium. That is why the administration of Ropren in addition to standard therapy is reasonable in patients with ACS.
Publisher
Cardiology Research Institute
Reference9 articles.
1. Karpov R. S., Dudko V. A. Atherosclerosis: pathogenesis, clinic, functional diagnostics, treatment. Tomsk: STT; 1998: 67. (In Russ).
2. Drapkina O. M., Bueverova E. L., Ivashkin V. T. Atherogenic dyslipidemia and liver. Atherosclerosis and dyslipidemia. 2010; 1: 25–31. (In Russ).
3. Drapkina O. M., Kostyukevich M. V. Metabolic syndrome: the problem of hepatotoxicity in the statins treatment. Atherosclerosis and dyslipidemia. 2011; 3: 45–51. (In Russ).
4. Bakunina N. S., Glushakov R. I., Tapilskaya N. I., Shabanov P. D. Pharmacology of polyprenols as adaptogens which reduce the intensity of glycation. Reviews of clinical pharmacology and drug therapy. 2013; 4(11):44–53. (In Russ).
5. Cantagrel V., Lefeber D. J., Ng B. G., Guan Z., Silhavy J. L., Bielas S. L., Lehle L., Hombauer H., Adamowicz M., Swiezewska E., De Brouwer A. P., Blümel P., Sykut-Cegielska J., Houliston S., Swistun D., Ali B. R., Dobyns W. B., Babovic-Vuksanovic D., van Bokhoven H., Wevers R. A., Raetz C. R., Freeze H. H., Morava E., AlGazali L., Gleeson J. G. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell. 2010; 142(2): 203–217.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献